RD Biomed

RD Biomed is a United Kingdom-based healthcare product development company focused on gastroenterology. According to its official website, the company describes itself as "an innovator in healthcare product development, with a focus on gastroenterology," and its activities span pharmaceutical development, clinical trials, and healthcare products. Its flagship offering is Peptest, an immunological in-vitro diagnostic medical device that rapidly detects the gastric enzyme pepsin in saliva, sputum, and exhaled breath condensate samples. The presence of pepsin in saliva or exhaled breath is an indicator of gastro-oesophageal reflux disease (GORD), which affects 20–30% of adults, or laryngopharyngeal reflux (LPR), often called "silent reflux." The company states that its products have been routinely used with patients in global gastroenterology, ENT, chest, and respiratory clinics, with wide use in paediatrics. RD Biomed has achieved ISO 13485:2016 certification, the internationally agreed standard specific to the medical devices industry. Its founder and director, Professor Peter Dettmar, is described as the author or co-author of more than 530 journal papers, abstracts, and book chapters on gastro-intestinal matters. Wikidata identifies RD Biomed Limited as a UK manufacturer of in-vitro diagnostic medical devices for reflux diagnosis, based in Hull. The company operates as a private entity and markets its diagnostic products internationally.

RD Biomed is a United Kingdom-based company specializing in healthcare product development with a focus on gastroenterology. It is headquartered in Hull, according to Wikidata, which describes it as a UK manufacturer of in-vitro diagnostic medical devices for reflux diagnosis. The company was founded by Professor Peter Dettmar, who serves as a director and is described on the company's website as the author or co-author of more than 530 journal papers, abstracts, and book chapters on gastro-intestinal matters. The company's flagship product, Peptest, is an immunological in-vitro diagnostic medical device that rapidly detects the gastric enzyme pepsin in saliva, sputum, and exhaled breath condensate samples. The presence of pepsin in these samples is an indicator of gastro-oesophageal reflux disease (GORD), which affects 20–30% of adults, or laryngopharyngeal reflux (LPR), often referred to as "silent reflux." Peptest is positioned as a non-invasive alternative to more costly and invasive procedures such as endoscopy; a testimonial on the company's website notes that Peptest's simplicity means patients do not have to be referred to secondary care, avoiding the expense of referral and endoscope procedures. RD Biomed's activities extend beyond diagnostics to include pharmaceutical development and clinical trials. The company states that its products have been routinely used with patients in global gastroenterology, ENT, chest, and respiratory clinics, and have wide use in paediatrics. It has achieved ISO 13485:2016 certification, the internationally agreed standard specific to the medical devices industry. The company markets its products worldwide and operates as a private entity.

Innovator in gastroenterology diagnostics; provider of non-invasive reflux testing.

• Peptest

  An immunological in-vitro diagnostic medical device that rapidly detects the gastric enzyme pepsin in saliva, sputum, and exhaled breath condensate samples, indicating gastro-oesophageal reflux disease (GORD) or laryngopharyngeal reflux (LPR).

1. 1Home - RD Biomedrdbiomed.com
2. 2RD Biomed Limited - Wikidatawikidata.org